Supplements and Compounds Library
Every article, presentation, spotlight, and news item we've tagged to Supplements and Compounds.
Showing 241–264 of 328
Senescent Microglia Mapping Reveals White Matter Targets
Senescent microglia accumulate in aged brain white matter and can be identified through spatial mapping techniques. Senotherapeutic interventions reduce this accumulation, suggesting a tractable target for preserving neurological function during aging.
Extracellular vesicles derived from senescent hepatocytes drive pan-cancer metastasis in aging
Senescent hepatocytes in aging release extracellular vesicles containing microRNAs that enhance metastatic potential across multiple cancer types in aged organisms. This mechanism directly links hepatic aging to systemic cancer progression, identifying a previously uncharacterized pathway connecting liver dysfunction to increased metastatic risk in older adults.
FOXM1 activation reverses endothelial aging in atherosclerosis
A platelet membrane-coated resveratrol nanoparticle system activates FOXM1 to restore mitochondrial function and reverse endothelial senescence in atherosclerosis models. The approach addresses both the bioavailability limitations of resveratrol and the cellular dysfunction underlying vascular pathology.
Progerin Blocks Its Own Clearance—Selinexor Restores the Pathway
Progerin, the mutant protein driving Hutchinson-Gilford progeria syndrome, blocks autophagy at its final stages—preventing lysosomes from clearing the toxic protein itself. Selinexor restores this clearance mechanism by reactivating the autophagy-lysosome pathway, offering a therapeutic target for this severe premature aging condition.
SIRT6 from centenarians addresses fatty liver in aging
Genflow Biosciences has advanced patent protection for a SIRT6 variant derived from centenarian genetics, designed to address non-alcoholic fatty liver disease and steatohepatitis. The company's lead candidate, GF-1002, entered proof-of-concept testing in aged dogs in March 2025, representing a translational step toward clinical validation in metabolic dysfunction.
Senescent Factors Suppress Innate Antiviral Immunity in Aged Mice via Two Distinct Mechanisms
Senescent cells accumulate with age and suppress antiviral immunity through four secreted factors—GDF15, IGF1, IL1α, and IL6—via two distinct signaling pathways. Blocking these factors restores innate antiviral defense in aged mice, offering a mechanistic target to improve immune resilience against infection in older adults.
Senescent Immune Cells Drive Tumor Invasion via Glutamine-IL-1β Axis
Oxidative stress triggers metabolic reprogramming in immune cells, causing them to secrete inflammatory factors that promote squamous cell carcinoma invasion. Blocking the IL-1β signaling pathway suppresses this invasion more effectively than targeting glutamine metabolism alone, suggesting a direct therapeutic intervention point.
Peptide Evidence Gap Closes With Transparent AI Reviews
Evipedia, the Forever Healthy Foundation's evidence platform, has launched a dedicated peptides section covering 24 compounds with structured, transparently auditable reviews using an AI-assisted framework. This addresses a critical gap in longevity medicine where peptide interventions have outpaced robust human evidence, creating a need for systematic assessment to distinguish hypothesis from clinical meaningfulness.
Thbs1 Blocks Bone Repair Through Immune Cell Mitochondrial Damage
Senescent bone marrow cells release thrombospondin-1 (Thbs1), which impairs mitochondrial cleanup in immune cells, driving chronic inflammation and blocking bone formation in aging. Blocking this protein restored bone repair in aged animals, identifying a specific therapeutic lever for age-related bone decline.
Adipose RNA Control Preserves Metabolic Flexibility in Aging
A long noncoding RNA called Lncbate1 regulates lipid synthesis in white adipose tissue during aging by modulating a microRNA-protein axis. This molecular mechanism reveals how aging alters fat storage and mobilization, with implications for metabolic decline and age-related disease prevention.
p21 + TREM2 + senescent macrophages fuel inflammaging and metabolic dysfunction-associated steatotic liver disease
Senescent macrophages expressing p21 and TREM2 accumulate with age and drive chronic inflammation and metabolic dysfunction in the liver. This identification of a specific senescent immune cell phenotype directly connects cellular aging to systemic metabolic decline and suggests a mechanistic target for interventions addressing age-related disease.
Senescence‐Driven Remodeling Defines an Aggressive and Immunomodulatory Subtype of Endometriosis
Cellular senescence in ectopic endometrial tissue drives aggressive endometriosis through a PAK4/AKT signaling loop that promotes macrophage-mediated immune remodeling. Stigmasterol, a plant-derived phytosterol, suppresses this pathway and reduces lesion invasiveness in preclinical models, suggesting a mechanism-based therapeutic approach to a senescence-driven disease subtype.
Senescent Cells Define Aggressive Endometriosis Subtype
A correction to prior research clarifies the classification of an aggressive endometriosis subtype characterized by cellular senescence and immune modulation. The findings refine understanding of how aging-related cellular changes drive pathological remodeling in endometrial tissue, with implications for stratifying disease severity and treatment response.
How a Sirtuin Protects Against Brain Diseases
SIRT6, a sirtuin protein, protects against neurodegenerative diseases by maintaining nucleolar function and constraining protein synthesis, preventing the accumulation of misfolded proteins that drives age-related brain pathology. This mechanism represents a direct intervention point in proteostasis failure, a primary driver of cognitive decline.
Estrogen Receptor Agonist Advances to Federal Lifespan Testing
LNS8801, a selective estrogen receptor agonist developed by Linnaeus Therapeutics, has been selected for lifespan testing by the National Institute on Aging's Interventions Testing Program, with concurrent federal funding to evaluate its effects on functional capacity and age-related decline. The drug's progression from oncology trials to dedicated longevity research reflects emerging evidence that certain receptor pathways may influence both disease prevention and healthspan preservation.
Aged Male Mice Remain Glucose Tolerant Despite Increased Energy Storage Efficiency Favoring Diet‐Induced Obesity
Aged male mice maintain glucose tolerance despite accumulating more fat on a high-fat diet than younger counterparts, a metabolic uncoupling driven by increased energy storage efficiency and reduced lipid turnover. This finding indicates that obesity and glucose dysregulation diverge with age, presenting distinct intervention targets for metabolic health in older populations.
Select Small Non‐Coding RNAs Are Determinants of Survival in Older Adults
Circulating small RNAs, particularly nine piRNAs, predict two-year survival in older adults with greater accuracy than age and clinical factors alone, with experimental evidence suggesting reduced piRNA levels associate with extended lifespan. These findings identify specific small RNA signatures as measurable biomarkers and potential therapeutic targets for longevity interventions.
FDA rewrites drug approval rules and longevity stands to gain
The FDA has shifted its drug approval standard from requiring two pivotal clinical trials to accepting one, citing advances in biological understanding, biomarker validation, and trial design sophistication. This regulatory change has direct implications for aging-related therapeutics, where slow biological processes and prevention-focused interventions have historically faced approval barriers under the two-trial requirement.
Gene therapy penetrates brain barrier safely without liver toxicity
JCR Pharmaceuticals has advanced a modified AAV gene therapy platform that achieves efficient central nervous system delivery while minimizing off-target hepatic expression. In preclinical models of lysosomal storage disorders, the platform extended survival, preserved neurological and retinal function, and reduced markers of neuroinflammation and cellular accumulation.
GPER Agonist Enters Rigorous Aging Validation Framework
LNS8801, a GPER-activating drug candidate from Linnaeus Therapeutics, has entered the National Institute on Aging's Interventions Testing Program—one of the most rigorous preclinical validation systems in longevity science. This milestone reflects a maturation in aging research: the field now prioritizes healthspan preservation alongside lifespan extension, moving beyond simple longevity metrics to functional capacity and disease resilience.
New peptide drugs on the horizon with PepLib–Lilly collab
Eli Lilly and PepLib Biotech have formed a collaboration to develop peptide-based therapeutics designed to target specific disease pathways with precision. Peptides represent a distinct therapeutic modality with applications in age-related conditions, metabolic dysfunction, and cardiovascular disease—key drivers of healthspan and lifespan limitations.
Primate RNA Accelerates Aging Through P53 Activation
A primate-specific regulatory RNA (LINC01021) accelerates cellular aging by destabilizing a protein that normally restrains the P53 pathway, establishing a molecular mechanism unique to primates. This discovery identifies an evolutionarily recent layer of genetic control that directly influences aging rate and frailty phenotypes.
Dopaminergic Cell Therapy Targets Neurodegeneration in Parkinson's
Aspen Neuroscience's sasineprocel, an autologous cell therapy derived from a patient's own skin cells and differentiated into dopaminergic neurons, has received FDA Regenerative Medicine Advanced Therapy designation for Parkinson's disease based on Phase 1/2a data showing early clinical activity and favorable safety. This designation accelerates regulatory pathway and marks a shift toward personalized cellular replacement strategies rather than pharmacological symptom management.
Senescence consortium targets biomarker gap
The Senotherapeutics Biomarker Consortium addresses a critical gap in senescence measurement standards across academia, industry, and regulators. Standardized biomarkers are essential to advance clinical translation of senotherapeutic interventions, as current measurement heterogeneity impedes trial reproducibility and regulatory confidence.